1401 related articles for article (PubMed ID: 31214177)
1. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
2. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
4. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
Zhuang X; Long EO
Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
[TBL] [Abstract][Full Text] [Related]
5. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
7. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
Rafei H; Daher M; Rezvani K
Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
[TBL] [Abstract][Full Text] [Related]
9. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
Mantesso S; Geerts D; Spanholtz J; Kučerová L
Front Immunol; 2020; 11():607131. PubMed ID: 33391277
[TBL] [Abstract][Full Text] [Related]
10. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor (CAR)-modified NK cells against cancer: Opportunities and challenges.
Wang L; Dou M; Ma Q; Yao R; Liu J
Int Immunopharmacol; 2019 Sep; 74():105695. PubMed ID: 31254958
[TBL] [Abstract][Full Text] [Related]
12. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
Schmidt P; Raftery MJ; Pecher G
Front Immunol; 2020; 11():611163. PubMed ID: 33488617
[TBL] [Abstract][Full Text] [Related]
13. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
15. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.
Hu Y; Tian ZG; Zhang C
Acta Pharmacol Sin; 2018 Feb; 39(2):167-176. PubMed ID: 28880014
[TBL] [Abstract][Full Text] [Related]
17. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.
Obajdin J; Davies DM; Maher J
Clin Exp Immunol; 2020 Oct; 202(1):11-27. PubMed ID: 32544282
[TBL] [Abstract][Full Text] [Related]
18. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
19. CAR-NK cells: A promising cellular immunotherapy for cancer.
Xie G; Dong H; Liang Y; Ham JD; Rizwan R; Chen J
EBioMedicine; 2020 Sep; 59():102975. PubMed ID: 32853984
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy.
Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV
J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
